12:00 AM
 | 
Oct 03, 2011
 |  BioCentury  |  Finance

Few Cinderellas this time

Big biotechs suffer least in 3Q11, as smaller cap groups drop as much as 25%

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other market cap groups shed 18-26%.

The best performer among the big caps was Alexion Pharmaceuticals Inc., which gained 36%. It was the only big cap that gained double digits.

Alexion shares bounced off an August bottom and continued rising through September on positive Phase II data for Soliris eculizumab to treat myasthenia gravis; an FDA approval for Soliris to treat atypical hemolytic uremic syndrome (aHUS); and a positive opinion by EMA's CHMP recommending approval of an MAA for Soliris to treat aHUS.

Soliris is already approved to treat paroxysmal nocturnal hemoglobinuria (PNH).

Dendreon Corp. was the worst-performing big cap last quarter. It fell 77% on weaker-than-expected sales of prostate cancer treatment Provenge sipuleucel-T.

Microarray and genetic services company Illumina Inc. dropped 46% on reduced guidance for EPS and revenue, as tool companies were hurt by concerns about cuts to research budgets.

Pharmasset Inc. soared in the $1-$4.9 billion market cap space, adding 47% on the quarter. It got a 7% boost on the last day of 3Q with positive Phase IIb data from its ELECTRON trial of PSI-7977 to treat HCV (see B23).

In September, the company reported additional positive data from the Phase IIb PROTON study of PSI-7977 from patients infected with HCV genotype 1. Pharmasset had already reported good data from that study for genotype 2 or 3.

Last quarter, Pharmasset also started the QUANTUM trial testing a combination of PSI-7977 and PSI-938, which the company noted is the first interferon-free, all-nucleotide study with a sustained virologic response (SVR) endpoint.

Jazz Pharmaceuticals Inc. gained 24% on a quarter that included the proposed acquisition of Ireland's Azur Pharma Ltd. The deal will reduce the combined company's tax rate to the mid-20% range.

In contrast, Alere Inc. shed 46% on its hostile offer for fellow diagnostic company Axis-Shield plc.

The worst performance in this group came from Human Genome Sciences Inc., which was dragged down 48% on launch fears after the Dendreon difficulties. The biotech and partner GlaxoSmithKline plc launched lupus drug Benlysta belimumab in the U.S. at the end of March and in Germany and Canada in August. Last Friday, NICE recommended against use of Benlysta in the U.K. (see Online Links, A25).

Another launch story in this group, InterMune Inc., also was hard hit by investor skepticism, falling 44% on the quarter.

InterMune launched Esbriet pirfenidone in Germany in September to treat idiopathic pulmonary fibrosis. It plans to launch the treatment in France, Spain and Italy in 1H12.

Unsightly under $1B

The market segments under $1 billion were all dragged down 22-26% as buysiders scrutinized balance sheets looking for at least a couple of years of cash.

The $500-$999 million group shed 25%, with only 5 of the 46 companies finishing in positive territory for the quarter.

An exception was Optimer Pharmaceuticals Inc., which launched Dificid fidaxomicin to treat Clostridium difficile-associated diarrhea (CDAD) along with partner Cubist Pharmaceuticals Inc. FDA approved Dificid in May. Optimer led this segment, adding 16% in 3Q.

Buysiders also liked Pharmacyclics Inc., which rose 13% last quarter on top of a big pop in 2Q.

Pharmacyclics' lead candidate, PCI-32765, is in Phase II testing for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL). These trials will report in the next 6-12 months.

The worst performances in this group came from Active Biotech AB and Pacific Biosciences of California Inc., which dropped 63% and 73%, respectively.

Active Biotech fell after oral laquinimod missed the primary endpoint in a Phase III trial to treat relapsing-remitting multiple sclerosis (RRMS), while Pacific Biosciences reported weak 2Q earnings and subsequently reduced headcount on slower-than-expected adoption of its PacBio RS sequencing products.

Acquisition stories accounted for the top 3Q gainers in the $200-$499 million market cap group. Axis-Shield gained 43%, while Caliper Life Sciences Inc. added 29% on its $600 million acquisition by PerkinElmer Inc.

Nabi Biopharmaceuticals fared the worst among the $200-$499 million market cap group, with a 69% decline after its NicVax nicotine vaccine missed the primary endpoint in a Phase III trial to treat nicotine addiction and prevent smoking relapse.

Siga Technologies Inc. shed 66%. The Delaware Court of Chancery awarded PharmAthene Inc. 50% of profits from the sale of Siga's ST-246 once Siga earns $40 million in net profits from the smallpox antiviral. ST-246 is in Phase II testing. Siga has said it will likely appeal.

In the sub-$200 million market cap group, Israeli company BioLineRx Ltd. got a boost of 77% after listing on NASDAQ. The neurology and cardiovascular play already was listed on the Tel Aviv exchange.

Among the notable microcap disappointments was Soligenix Inc., which was down 82% on the discontinuation of a Phase III trial of orBec beclomethasone dipropionate to treat acute gastrointestinal graft-versus-host disease (GvHD). An interim analysis showed it was unlikely to meet the primary endpoint.

Also, NuPathe Inc. dropped 72% on a complete response letter for an...

Read the full 4401 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >